MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

November 11, 2009

“This is the first reported epidemic of dengue fever in Cape Verde and it is huge,” said Dr. Iza Ciglenecki, MSF’s emergency coordinator in Cape Verde. “With globalization, dengue fever is appearing in places where it has previously been unknown. It is the most rapidly spreading mosquito-borne disease in the world.”

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

November 11, 2009

“This is the first reported epidemic of dengue fever in Cape Verde and it is huge,” said Dr. Iza Ciglenecki, MSF’s emergency coordinator in Cape Verde. “With globalization, dengue fever is appearing in places where it has previously been unknown. It is the most rapidly spreading mosquito-borne disease in the world.”